Novel therapeutic agents for treatment of endometrial cancer

Kouji Banno, Miho Iida, Samir A. Farghaly, Kiyoko Umene, Iori Kisu, Daisuke Aoki

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Endometrial cancer is a female genital cancer that occurs frequently in Europe and the United States. Conventional therapy for endometrial cancer does not permit fertility preservation or have effects on advanced and recurrent cancers, and new pharmacotherapies are needed. The fourth-generation progestin, dienogest, blocks excessive estrogenic activity and inhibits endometrial overgrowth. Metformin is an antidiabetic drug that may have an effect on endometrial cancer through targeting of the mammalian target of rapamycin (mTOR) pathway. mTOR inhibitors block cancer growth by arresting the cell cycle in G1 phase and clinical trials of new generation drugs with multiple sites of action in the mTOR pathway are underway. To inhibit down regulation of tumor suppressor genes by DNA hypermethylation and histone deacetylation, drugs targeting DNA methyltransferase (DNMT), microRNA (miRNA) and histone deacetylase (HDAC) are under development. AEZS-108 targeted to LHRH receptors on tumors is an effective compound for chemotherapy of endometrial cancer. In addition, targeting STAT3 or Wnt/β-catenin pathway by specific inhibitor in tumor cells and immunosuppressive cells, or along with other immunotherapy, might restore the immunocompetence of endometrial cancer patients. The oncogenic mechanisms underlying endometrial cancer, and regulatory factors based on the characteristics of endometrial cancer cells are gradually emerging. These data are likely to lead to development of new effective therapy for this disease.

Original languageEnglish
Title of host publicationEndometrial Cancer: Current Epidemiology, Detection and Management
PublisherNova Science Publishers, Inc.
Pages321-337
Number of pages17
ISBN (Print)9781634631945, 9781634631631
Publication statusPublished - 2014 Oct 1

Fingerprint

Endometrial Neoplasms
Sirolimus
dienogest
Neoplasms
Therapeutics
Fertility Preservation
LHRH Receptors
Immunocompetence
Drug Therapy
Catenins
Wnt Signaling Pathway
Histone Deacetylases
Metformin
DNA
Methyltransferases
G1 Phase
Progestins
Drug Delivery Systems
Immunosuppressive Agents
Tumor Suppressor Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Banno, K., Iida, M., Farghaly, S. A., Umene, K., Kisu, I., & Aoki, D. (2014). Novel therapeutic agents for treatment of endometrial cancer. In Endometrial Cancer: Current Epidemiology, Detection and Management (pp. 321-337). Nova Science Publishers, Inc..

Novel therapeutic agents for treatment of endometrial cancer. / Banno, Kouji; Iida, Miho; Farghaly, Samir A.; Umene, Kiyoko; Kisu, Iori; Aoki, Daisuke.

Endometrial Cancer: Current Epidemiology, Detection and Management. Nova Science Publishers, Inc., 2014. p. 321-337.

Research output: Chapter in Book/Report/Conference proceedingChapter

Banno, K, Iida, M, Farghaly, SA, Umene, K, Kisu, I & Aoki, D 2014, Novel therapeutic agents for treatment of endometrial cancer. in Endometrial Cancer: Current Epidemiology, Detection and Management. Nova Science Publishers, Inc., pp. 321-337.
Banno K, Iida M, Farghaly SA, Umene K, Kisu I, Aoki D. Novel therapeutic agents for treatment of endometrial cancer. In Endometrial Cancer: Current Epidemiology, Detection and Management. Nova Science Publishers, Inc. 2014. p. 321-337
Banno, Kouji ; Iida, Miho ; Farghaly, Samir A. ; Umene, Kiyoko ; Kisu, Iori ; Aoki, Daisuke. / Novel therapeutic agents for treatment of endometrial cancer. Endometrial Cancer: Current Epidemiology, Detection and Management. Nova Science Publishers, Inc., 2014. pp. 321-337
@inbook{46506d14184244a2a90c7391124840cf,
title = "Novel therapeutic agents for treatment of endometrial cancer",
abstract = "Endometrial cancer is a female genital cancer that occurs frequently in Europe and the United States. Conventional therapy for endometrial cancer does not permit fertility preservation or have effects on advanced and recurrent cancers, and new pharmacotherapies are needed. The fourth-generation progestin, dienogest, blocks excessive estrogenic activity and inhibits endometrial overgrowth. Metformin is an antidiabetic drug that may have an effect on endometrial cancer through targeting of the mammalian target of rapamycin (mTOR) pathway. mTOR inhibitors block cancer growth by arresting the cell cycle in G1 phase and clinical trials of new generation drugs with multiple sites of action in the mTOR pathway are underway. To inhibit down regulation of tumor suppressor genes by DNA hypermethylation and histone deacetylation, drugs targeting DNA methyltransferase (DNMT), microRNA (miRNA) and histone deacetylase (HDAC) are under development. AEZS-108 targeted to LHRH receptors on tumors is an effective compound for chemotherapy of endometrial cancer. In addition, targeting STAT3 or Wnt/β-catenin pathway by specific inhibitor in tumor cells and immunosuppressive cells, or along with other immunotherapy, might restore the immunocompetence of endometrial cancer patients. The oncogenic mechanisms underlying endometrial cancer, and regulatory factors based on the characteristics of endometrial cancer cells are gradually emerging. These data are likely to lead to development of new effective therapy for this disease.",
author = "Kouji Banno and Miho Iida and Farghaly, {Samir A.} and Kiyoko Umene and Iori Kisu and Daisuke Aoki",
year = "2014",
month = "10",
day = "1",
language = "English",
isbn = "9781634631945",
pages = "321--337",
booktitle = "Endometrial Cancer: Current Epidemiology, Detection and Management",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Novel therapeutic agents for treatment of endometrial cancer

AU - Banno, Kouji

AU - Iida, Miho

AU - Farghaly, Samir A.

AU - Umene, Kiyoko

AU - Kisu, Iori

AU - Aoki, Daisuke

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Endometrial cancer is a female genital cancer that occurs frequently in Europe and the United States. Conventional therapy for endometrial cancer does not permit fertility preservation or have effects on advanced and recurrent cancers, and new pharmacotherapies are needed. The fourth-generation progestin, dienogest, blocks excessive estrogenic activity and inhibits endometrial overgrowth. Metformin is an antidiabetic drug that may have an effect on endometrial cancer through targeting of the mammalian target of rapamycin (mTOR) pathway. mTOR inhibitors block cancer growth by arresting the cell cycle in G1 phase and clinical trials of new generation drugs with multiple sites of action in the mTOR pathway are underway. To inhibit down regulation of tumor suppressor genes by DNA hypermethylation and histone deacetylation, drugs targeting DNA methyltransferase (DNMT), microRNA (miRNA) and histone deacetylase (HDAC) are under development. AEZS-108 targeted to LHRH receptors on tumors is an effective compound for chemotherapy of endometrial cancer. In addition, targeting STAT3 or Wnt/β-catenin pathway by specific inhibitor in tumor cells and immunosuppressive cells, or along with other immunotherapy, might restore the immunocompetence of endometrial cancer patients. The oncogenic mechanisms underlying endometrial cancer, and regulatory factors based on the characteristics of endometrial cancer cells are gradually emerging. These data are likely to lead to development of new effective therapy for this disease.

AB - Endometrial cancer is a female genital cancer that occurs frequently in Europe and the United States. Conventional therapy for endometrial cancer does not permit fertility preservation or have effects on advanced and recurrent cancers, and new pharmacotherapies are needed. The fourth-generation progestin, dienogest, blocks excessive estrogenic activity and inhibits endometrial overgrowth. Metformin is an antidiabetic drug that may have an effect on endometrial cancer through targeting of the mammalian target of rapamycin (mTOR) pathway. mTOR inhibitors block cancer growth by arresting the cell cycle in G1 phase and clinical trials of new generation drugs with multiple sites of action in the mTOR pathway are underway. To inhibit down regulation of tumor suppressor genes by DNA hypermethylation and histone deacetylation, drugs targeting DNA methyltransferase (DNMT), microRNA (miRNA) and histone deacetylase (HDAC) are under development. AEZS-108 targeted to LHRH receptors on tumors is an effective compound for chemotherapy of endometrial cancer. In addition, targeting STAT3 or Wnt/β-catenin pathway by specific inhibitor in tumor cells and immunosuppressive cells, or along with other immunotherapy, might restore the immunocompetence of endometrial cancer patients. The oncogenic mechanisms underlying endometrial cancer, and regulatory factors based on the characteristics of endometrial cancer cells are gradually emerging. These data are likely to lead to development of new effective therapy for this disease.

UR - http://www.scopus.com/inward/record.url?scp=84958012888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958012888&partnerID=8YFLogxK

M3 - Chapter

SN - 9781634631945

SN - 9781634631631

SP - 321

EP - 337

BT - Endometrial Cancer: Current Epidemiology, Detection and Management

PB - Nova Science Publishers, Inc.

ER -